Bio-Techne Showcases Next-Generation Solutions for Gene and Cell Therapy at ASGCT 2025
Bio-Techne Corporation (NASDAQ: TECH) is set to participate in the prestigious American Society of Gene & Cell Therapy (ASGCT) 2025 conference, taking place from May 13 to 17 in New Orleans. The event, held at the New Orleans Ernest N. Morial Convention Center, promises a gathering of leading researchers and practitioners dedicated to advancing the frontiers of gene and cell therapy.
Innovative Solutions on Display
At booth 1537, Bio-Techne will present its latest advancements in spatial biology and therapy workflows tailored for next-generation gene and cell therapy applications. Of particular interest will be the introduction of the
RNAscope™ protease-free workflow, notable for its capabilities in visualizing biodistribution of various elements such as AAV vectors, transgene mRNA, small RNAs (including ASO, siRNA, and miRNA), along with functional RNA and protein markers. This innovative technology is a game changer for researchers aiming to better understand the complexities of gene therapy mechanisms.
Additionally, attendees will have the opportunity to explore Bio-Techne's solutions that enhance cell therapy workflows. This includes the
ProPak™ GMP cytokines packaged in dose-optimized, single-use bags, complete with weldable tubing designed for use in closed-system cell therapy manufacturing. The emphasis on closed systems is a significant step towards improving the safety and efficacy of cell therapies. Bio-Techne will also feature its
next-generation Simple Western Leo™ System, which stands out as a state-of-the-art instrument capable of processing up to 100 samples in just a three-hour session. This advanced system is designed to expedite the workflow, allowing researchers to focus on their findings rather than lengthy processing times.
Expert Talks and Presentations
The conference will not only showcase the latest technologies but also host an array of expert-led discussions. Notables in the field, including
Maithreyan Srinivasan, PhD, Chief Scientific Officer at Advanced Cell Diagnostics (ACD), a Bio-Techne brand, will lead insights into cutting-edge RNAscope technology during a symposium scheduled for May 14 at 8:30 AM in room 383-385. This session promises to illuminate the
NextGen RNAscope™ Multiomics Solutions, emphasizing spatial precision in various innovative applications.
Adrian Veres, MD, PhD, Cofounder and Chief Scientific Officer at Dyno Therapeutics, will share insights on the validation of AI-designed AAV capsids aimed at targeted gene delivery to non-human primates (NHPs). In a thought-provoking academic discussion,
William (Wes) Salomon, PhD, Senior Director at Tessera Therapeutics, will address visualizing RNA gene writer activity in mouse liver, a potential approach for therapeutic correction of monogenic disease mutations.
Moreover, the role of protein quantitation in advancing gene therapy will be discussed on May 15 from 12:15 PM to 1:15 PM by
Edward Pavina (Bio-Techne) along with guest speakers and experts from
Sangamo Therapeutics and
Nervosave Therapeutics. This panel discussion will explore how precise protein quantification can drive forward the development of gene therapies, from foundational discovery through subsequent analytical phases.
A Commitment to Advance Therapeutics
“Bio-Techne is at the cutting edge of developing tools and technologies that are essential for pushing the boundaries of cell and gene therapy,” remarked
Kim Kelderman, President and CEO of Bio-Techne. “The ASGCT conference represents a pivotal opportunity to delve into the latest innovations, fostering the development of safe and effective therapies for a wide range of disorders.”
For research purposes only, Bio-Techne continues to be a pivotal contributor in the scientific community, aiding in the understanding of complex biological processes and advancing therapeutic development. With a portfolio featuring hundreds of thousands of products and an unyielding commitment to innovation, Bio-Techne exemplifies leadership in bioactive reagents and diagnostic tools.
To know more about Bio-Techne and its contributions to research and clinical diagnostics, visit
Bio-Techne's website. Follow their latest updates on social media platforms such as Facebook, LinkedIn, Twitter, and YouTube.